Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ACLX

Arcellx Inc

Dec 27 • 04:00PM ET

79.08

Dollar change +0.06
Percentage change 0.08	%

Healthcare • Biotechnology • USA • NASD

Peers: ALLO GILD CRSP NTLA FATE EDIT BLUE SGMO PSTX VCNX

| Held by: VTI IWM XBI VXF IWO IBB VTWO SCHA VHT LABU

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.75	Insider Own	24.58%	Shs Outstand	53.99M	Perf Week	5.15%
Market Cap	4.28B	Forward P/E	-	EPS next Y	-2.28	Insider Trans	-1.59%	Shs Float	40.78M	Perf Month	-13.06%
Income	-40.42M	PEG	-	EPS next Q	-0.55	Inst Own	81.58%	Short Float	13.37%	Perf Quarter	-4.45%
Sales	155.82M	P/S	27.46	EPS this Y	-9.24%	Inst Trans	2.42%	Short Ratio	9.46	Perf Half Y	43.29%
Book/sh	8.95	P/B	8.84	EPS next Y	-42.25%	ROA	-5.86%	Short Interest	5.45M	Perf Year	37.32%
Cash/sh	10.62	P/C	7.45	EPS next 5Y	-	ROE	-10.79%	52W Range	47.88 - 107.37	Perf YTD	42.49%
Dividend Est.	-	P/FCF	1195.38	EPS past 5Y	-29.89%	ROI	-7.62%	52W High	-26.35%	Beta	0.29
Dividend TTM	-	Quick Ratio	4.29	Sales past 5Y	0.00%	Gross Margin	97.36%	52W Low	65.16%	ATR (14)	4.39
Dividend Ex-Date	-	Current Ratio	4.29	EPS Y/Y TTM	73.14%	Oper. Margin	-44.55%	RSI (14)	42.19	Volatility	3.78% 5.70%
Employees	130	Debt/Eq	0.14	Sales Y/Y TTM	230.33%	Profit Margin	-25.94%	Recom	1.21	Target Price	116.38
Option/Short	Yes / Yes	LT Debt/Eq	0.10	EPS Q/Q	40.82%	Payout	-	Rel Volume	0.83	Prev Close	79.02
Sales Surprise	-32.78%	EPS Surprise	-54.99%	Sales Q/Q	74.03%	Earnings	Nov 07 AMC	Avg Volume	576.11K	Price	79.08
SMA20	-4.31%	SMA50	-9.79%	SMA200	14.30%	Trades		Volume	478,839	Change	0.08%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-08-24	Initiated	Redburn Atlantic	Buy	$109
Sep-03-24	Initiated	Cantor Fitzgerald	Overweight
May-31-24	Initiated	Piper Sandler	Overweight	$70
Mar-07-24	Initiated	Morgan Stanley	Overweight	$81
Jan-04-24	Reiterated	Needham	Buy	$65 → $71
Dec-19-23	Initiated	Scotiabank	Sector Outperform	$66
Oct-30-23	Initiated	TD Cowen	Outperform
Oct-17-23	Initiated	UBS	Buy	$52
May-18-23	Initiated	Truist	Buy	$60
Apr-14-23	Initiated	Robert W. Baird	Outperform	$39
Mar-14-23	Initiated	Stifel	Buy	$43
Feb-13-23	Initiated	H.C. Wainwright	Buy	$42
Dec-13-22	Resumed	BofA Securities	Buy	$29 → $37
Oct-31-22	Initiated	Guggenheim	Buy	$36
Oct-27-22	Initiated	Needham	Buy	$31
Jul-20-22	Initiated	Canaccord Genuity	Buy	$32
Mar-01-22	Initiated	SVB Leerink	Outperform	$47
Mar-01-22	Initiated	BofA Securities	Buy	$24

Show Previous Ratings

Dec-27-24 02:09PM	Arcellx Stock Earns 82 Relative Strength Rating (Investor's Business Daily)
Dec-10-24 09:00PM	ASH 2024: Arcellx publishes positive results for Anito-cel in multiple myeloma (Clinical Trials Arena) +5.73%
Dec-09-24 04:22PM	Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead. (Investor's Business Daily)
07:50AM	Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients (Benzinga)
Dec-08-24 11:00PM	Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition (Business Wire)
12:00PM	Loading…
Nov-13-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Arcellx, Inc. (ACLX) is a Great Choice (Zacks)
Nov-08-24 09:40AM	Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-07-24 05:15PM	Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +6.65%
04:00PM	Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights (Business Wire)
06:41AM	Arcellx price target raised to $106 from $81 at Morgan Stanley (TipRanks)
06:27AM	Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar? (Zacks)
Nov-05-24 09:00AM	Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study (Business Wire)
07:19AM	Cancer cell therapy from Arcellx, Gilead shows promise in early data (BioPharma Dive)
Oct-31-24 10:43PM	Arcellx (ACLX) Surged in Q3. Heres Why (Insider Monkey)
Aug-08-24 05:25PM	Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +12.31%
04:00PM	Loading…
04:00PM	Arcellx Provides Second Quarter 2024 Financial Results and Business Updates (Business Wire)
Aug-02-24 06:53AM	Heres Why Arcellx (ACLX) Slipped in Q2 (Insider Monkey) -5.69%
Jul-04-24 02:13PM	FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals (InvestorPlace)
Jun-29-24 03:08AM	Insider Sale: CFO Michelle Gilson Sells 12,877 Shares of Arcellx Inc (ACLX) (GuruFocus.com)
Jun-21-24 04:42PM	Arcellx Stock Earns Relative Strength Rating Upgrade (Investor's Business Daily)
May-27-24 12:32PM	7 Biotech Stocks to Put on Your Breakthrough Radar (InvestorPlace)
May-25-24 03:11AM	Insider Sale: CFO Michelle Gilson Sells Shares of Arcellx Inc (ACLX) (GuruFocus.com)
May-17-24 08:06AM	Private Equity Prowl: 3 Overlooked Stocks Primed for Buyout Bids (InvestorPlace)
May-15-24 07:21AM	Stifel Adjusts Price Target on Arcellx to $83 From $82, Maintains Buy Rating (MT Newswires)
May-14-24 08:00AM	Evercore ISI Starts Arcellx With Outperform Rating (MT Newswires)
May-10-24 01:13PM	Arcellx Inc (ACLX) Q1 2024 Earnings: Narrower Losses and Revenue Surge (GuruFocus.com) -5.67%
04:21AM	Kite and Arcellx prepare to launch Phase III multiple myeloma trial (Clinical Trials Arena)
May-09-24 10:57PM	ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:10PM	Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program (Business Wire)
04:05PM	Loading…
04:05PM	Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program (Business Wire)
04:00PM	Arcellx Provides First Quarter 2024 Financial Results (Business Wire)
06:49AM	Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine (InvestorPlace)
May-07-24 04:00PM	Arcellx to Participate in Two Upcoming Investor Conferences (Business Wire)
May-03-24 05:57PM	Arcellx Insider Sold Shares Worth $932,557, According to a Recent SEC Filing (MT Newswires)
Apr-23-24 11:26AM	Should You Be Bullish on Arcellx (ACLX)? (Insider Monkey)
Apr-04-24 04:00PM	Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
08:40AM	How Arcellx (ACLX) Stock Stands Out in a Strong Industry (Zacks)
Mar-29-24 02:57PM	Dell, Dun & Bradstreet, Diebold Nixdorf, and More Stocks See Action From Activist Investors (Barrons.com)
Mar-28-24 08:13AM	Insiders Are Dumping These 10 Healthcare Stocks (Insider Monkey)
Mar-27-24 01:50AM	Insider Sell: Arcellx Inc's Chief Medical Officer Christopher Heery Disposes of 46,815 Shares (GuruFocus.com)
Mar-20-24 04:00PM	Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference (Business Wire)
Feb-29-24 04:00PM	Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference (PR Newswire)
Feb-28-24 07:30PM	Arcellx, Inc. (ACLX) Q4 Earnings and Revenues Surpass Estimates (Zacks)
04:00PM	Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights (PR Newswire)
Feb-15-24 11:57AM	The 3 Biotech Stocks That Could Make Your February Unforgettable (InvestorPlace)
Jan-16-24 01:51PM	Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market (InvestorPlace)
Dec-22-23 01:30AM	Chief Medical Officer Christopher Heery Sells 120,000 Shares of Arcellx Inc (GuruFocus.com)
Dec-15-23 05:04PM	Pharmas Frontline: 3 Stocks Driving Revolutionary Drug Development (InvestorPlace)
Dec-08-23 04:00PM	Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH (PR Newswire) -6.87%
Nov-30-23 09:37PM	3 Biotech Stocks That Could Be Multibaggers in the Making (InvestorPlace)
Nov-21-23 08:00AM	These Stocks Are Exploding In The November Stock Market Rally (Investor's Business Daily)
Nov-16-23 10:10AM	Arcellx (ACLX) Up 5% on Partnership Expansion With Gilead (Zacks)
Nov-15-23 04:05PM	Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead (Investor's Business Daily) +5.31%
09:47AM	Arcellx Stock Surges as Gilead Adds to Stake, Expands Collaboration (Barrons.com)
09:22AM	Gilead hands Arcellx $285M to expand BCMA cell therapy deal, sparking fresh push for congested market (FierceBiotech.com)
07:16AM	Gilead expands Arcellx cancer cell therapy deal (BioPharma Dive)
06:00AM	Kite and Arcellx Announce Expansion in Strategic Partnership (Business Wire)
06:00AM	ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP (PR Newswire)
Nov-13-23 04:47PM	Arcellx Inc (ACLX) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
04:00PM	Arcellx Provides Third Quarter 2023 Financial Results and Business Highlights (PR Newswire)
Nov-09-23 11:14AM	There Were 181 IPOs In 2022: $1K In Either Of These Two Would Have You Up 200%+ (Benzinga)
08:30AM	Is a Surprise Coming for Arcellx (ACLX) This Earnings Season? (Zacks)
Nov-02-23 09:40AM	Are Medical Stocks Lagging Arcellx (ACLX) This Year? (Zacks) +18.55%
09:00AM	Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 65th ASH Annual Meeting and Exposition (PR Newswire)
Oct-26-23 04:00PM	Arcellx to Participate in Two Upcoming Investor Conferences (PR Newswire)
Oct-23-23 02:50AM	7 Biotech Stocks to Get In Now Before Investors Catch On (InvestorPlace)
Oct-17-23 09:40AM	Is Arcellx (ACLX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-29-23 12:43PM	25 Biggest Stocks with Negative Beta (Insider Monkey)
Sep-04-23 09:55AM	Wall Street Analysts Believe Arcellx, Inc. (ACLX) Could Rally 35.56%: Here's is How to Trade (Zacks)
Sep-01-23 09:18AM	5 Biotech Stocks to Buy as New Drug Approvals Drive Industry Prospects (Zacks)
Aug-17-23 09:55AM	Does Arcellx, Inc. (ACLX) Have the Potential to Rally 39.12% as Wall Street Analysts Expect? (Zacks)
Aug-16-23 01:21PM	Gilead (GILD), Tentarix To Develop Cancer, Inflammation Therapies (Zacks)
Aug-14-23 04:00PM	Arcellx Announces Partial Clinical Hold Lifted on iMMagine-1 Phase 2 Clinical Program and Reports Second Quarter Financial Results (PR Newswire) +6.62%
Jul-31-23 07:13AM	Arcellx's (NASDAQ:ACLX) investors will be pleased with their respectable 51% return over the last year (Simply Wall St.)
Jul-25-23 02:37AM	Should You be Bullish on Arcellx (ACLX)? (Insider Monkey)
Jun-26-23 12:48PM	Gilead (GILD) Breast Cancer Drug Gets Positive CHMP Opinion (Zacks)
Jun-22-23 11:04AM	Biotech Stock Roundup: DICE Gains on LLY Buyout, MRSN Down on Update & More (Zacks)
Jun-21-23 10:38AM	Arcellx (RCLX) Down on Hold for Lead Program CART-ddBCMA (Zacks)
Jun-20-23 04:05PM	Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death (Investor's Business Daily) -7.18%
Jun-19-23 07:46PM	Arcellx Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program (PR Newswire)
May-11-23 10:45AM	Top Small-Cap Stocks for May 2023 (Investopedia)
May-10-23 06:11AM	Results: Arcellx, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts (Simply Wall St.)
May-08-23 05:15PM	Arcellx, Inc. (ACLX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:00PM	Arcellx Provides First Quarter Financial Results (PR Newswire)
May-04-23 04:59AM	Zacks.com featured highlights Arcellx, Harrow Health, PROG, Chipotle Mexican Grill and Meta (Zacks)
May-03-23 06:44AM	5 Stocks With Recent Price Strength That Still Have Upside (Zacks)
Apr-28-23 03:34PM	Gilead Sciences (GILD) Q1 2023 Earnings Call Transcript (Motley Fool)
Apr-25-23 12:00PM	Arcellx, Inc. (ACLX) is a Great Momentum Stock: Should You Buy? (Zacks)
Apr-21-23 12:00PM	Arcellx, Inc. (ACLX) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +8.50%
Apr-13-23 04:01PM	Arcellx to Participate at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference (PR Newswire) +5.84%
Apr-11-23 10:00AM	Best Momentum Stocks to Buy for April 11th (Zacks)
Apr-05-23 09:55AM	Wall Street Analysts Predict a 29.58% Upside in Arcellx, Inc. (ACLX): Here's What You Should Know (Zacks)
Apr-04-23 12:20PM	Earnings Estimates Moving Higher for Arcellx, Inc. (ACLX): Time to Buy? (Zacks)
Apr-03-23 08:34AM	Do Options Traders Know Something About Arcellx (ACLX) Stock We Don't? (Zacks)
Mar-29-23 05:25PM	Arcellx, Inc. (ACLX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Arcellx Provides Fourth Quarter and Year-End 2022 Financial Results and Business Highlights (PR Newswire)
Mar-16-23 12:18PM	Is a Surprise Coming for Arcellx (ACLX) This Earnings Season? (Zacks)
Feb-21-23 04:00PM	Arcellx to Participate at the H.C. Wainwright Cell Therapy Virtual Conference (PR Newswire) -5.09%
Feb-02-23 04:00PM	Arcellx to Participate in Upcoming Investor Conferences (PR Newswire)

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Gaithersburg, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Patel Kavita	Director	Dec 24 '24	Option Exercise	6.66	1,500	9,990	1,500	Dec 26 08:42 PM
Patel Kavita	Director	Dec 24 '24	Sale	76.97	1,500	115,451	0	Dec 26 08:42 PM
Patel Kavita	Director	Dec 03 '24	Option Exercise	6.66	1,500	9,990	1,500	Dec 05 05:58 PM
Patel Kavita	Director	Dec 03 '24	Sale	91.88	1,500	137,818	0	Dec 05 05:58 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Nov 19 '24	Option Exercise	8.66	3,000	25,980	3,000	Nov 19 06:46 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Nov 15 '24	Sale	88.87	1,761	156,508	0	Nov 19 06:46 PM
Patel Kavita	Director	Nov 12 '24	Option Exercise	6.66	1,500	9,990	1,500	Nov 14 04:37 PM
Patel Kavita	Director	Nov 12 '24	Sale	106.33	1,500	159,495	0	Nov 14 04:37 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Nov 08 '24	Option Exercise	8.66	7,200	62,352	14,115	Nov 12 08:31 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Nov 08 '24	Sale	100.55	12,354	1,242,170	1,761	Nov 12 08:31 PM
Patel Kavita	Director	Nov 08 '24	Option Exercise	13.03	33,763	439,925	33,763	Nov 12 08:30 PM
Patel Kavita	Director	Nov 11 '24	Option Exercise	15.00	15,238	228,570	15,238	Nov 12 08:30 PM
Patel Kavita	Director	Nov 07 '24	Option Exercise	6.66	8,478	56,463	8,478	Nov 12 08:30 PM
Patel Kavita	Director	Nov 08 '24	Sale	104.14	33,763	3,515,941	0	Nov 12 08:30 PM
Patel Kavita	Director	Nov 11 '24	Sale	105.92	15,238	1,614,006	0	Nov 12 08:30 PM
Patel Kavita	Director	Nov 07 '24	Sale	99.30	8,478	841,861	0	Nov 12 08:30 PM
KAVITA K PATEL	Director	Nov 08 '24	Proposed Sale	99.16	45,003	4,462,497		Nov 08 04:41 PM
MICHELLE GILSON	Officer	Nov 08 '24	Proposed Sale	99.16	14,115	1,399,643		Nov 08 04:30 PM
KAVITA K PATEL	Director	Nov 07 '24	Proposed Sale	92.98	13,976	1,299,488		Nov 07 04:33 PM
Patel Kavita	Director	Oct 22 '24	Option Exercise	6.66	1,500	9,990	1,500	Oct 22 06:48 PM
Patel Kavita	Director	Oct 22 '24	Sale	89.69	1,500	134,535	0	Oct 22 06:48 PM
KAVITA K PATEL	Director	Oct 22 '24	Proposed Sale	90.28	7,500	677,100		Oct 22 04:23 PM
Patel Kavita	Director	Oct 01 '24	Option Exercise	6.66	1,500	9,990	1,500	Oct 03 04:00 PM
Patel Kavita	Director	Oct 01 '24	Sale	82.24	1,500	123,360	0	Oct 03 04:00 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Sep 17 '24	Option Exercise	8.66	15,000	129,900	21,915	Sep 17 08:54 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Sep 17 '24	Sale	77.73	15,000	1,165,880	6,915	Sep 17 08:54 PM
MICHELLE GILSON	Officer	Sep 17 '24	Proposed Sale	77.01	15,000	1,155,150		Sep 17 04:39 PM
Patel Kavita	Director	Sep 10 '24	Option Exercise	6.66	1,500	9,990	1,500	Sep 12 06:27 PM
Patel Kavita	Director	Sep 10 '24	Sale	74.41	1,500	111,615	0	Sep 12 06:27 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Sep 05 '24	Option Exercise	15.00	3,421	51,315	12,699	Sep 06 05:48 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Sep 05 '24	Sale	70.02	3,421	239,526	9,278	Sep 06 05:48 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Sep 03 '24	Option Exercise	13.27	27,451	364,232	36,729	Sep 03 09:33 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Sep 03 '24	Sale	67.03	27,451	1,840,053	9,278	Sep 03 09:33 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Aug 26 '24	Option Exercise	15.00	21,684	325,260	30,962	Aug 28 04:54 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Aug 26 '24	Sale	71.12	21,684	1,542,274	9,278	Aug 28 04:54 PM
CHRISTOPHER HEERY	Officer	Aug 26 '24	Proposed Sale	69.38	48,907	3,393,168		Aug 26 04:24 PM
Patel Kavita	Director	Aug 20 '24	Option Exercise	6.66	1,500	9,990	1,500	Aug 22 04:01 PM
Patel Kavita	Director	Aug 20 '24	Sale	65.88	1,500	98,820	0	Aug 22 04:01 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Aug 16 '24	Option Exercise	6.28	5,450	34,226	14,728	Aug 19 04:39 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Aug 16 '24	Sale	65.05	5,450	354,526	9,278	Aug 19 04:39 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Aug 01 '24	Option Exercise	10.94	20,000	218,764	29,278	Aug 02 04:02 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Aug 01 '24	Sale	60.42	20,000	1,208,435	9,278	Aug 02 04:02 PM
Patel Kavita	Director	Jul 30 '24	Option Exercise	6.66	1,500	9,990	1,500	Aug 01 05:24 PM
Patel Kavita	Director	Jul 30 '24	Sale	61.97	1,500	92,949	0	Aug 01 05:24 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jul 16 '24	Option Exercise	6.28	10,901	68,458	20,179	Jul 18 06:44 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jul 16 '24	Sale	65.30	10,901	711,854	9,278	Jul 18 06:44 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jul 11 '24	Option Exercise	6.28	3,671	23,054	12,949	Jul 12 06:39 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jul 12 '24	Option Exercise	6.28	1,780	11,178	11,058	Jul 12 06:39 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jul 11 '24	Sale	60.01	3,671	220,302	9,278	Jul 12 06:39 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jul 12 '24	Sale	60.21	1,780	107,175	9,278	Jul 12 06:39 PM
Patel Kavita	Director	Jul 09 '24	Option Exercise	6.66	1,500	9,990	1,500	Jul 11 04:04 PM
Patel Kavita	Director	Jul 09 '24	Sale	56.63	1,500	84,947	0	Jul 11 04:04 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jul 01 '24	Option Exercise	11.93	20,000	238,646	29,278	Jul 03 04:05 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jul 01 '24	Sale	55.39	20,000	1,107,763	9,278	Jul 03 04:05 PM
Patel Kavita	Director	Jun 27 '24	Option Exercise	6.66	10,000	66,600	10,000	Jun 28 04:08 PM
Patel Kavita	Director	Jun 27 '24	Sale	54.27	10,000	542,656	0	Jun 28 04:08 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Jun 26 '24	Sale	53.70	12,877	691,519	6,915	Jun 28 04:06 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jun 12 '24	Option Exercise	11.53	20,000	230,554	29,278	Jun 14 04:31 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jun 12 '24	Sale	55.13	20,000	1,102,668	9,278	Jun 14 04:31 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	May 23 '24	Option Exercise	0.00	22,428	0	31,913	May 24 08:16 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	May 24 '24	Sale	50.71	12,121	614,656	19,792	May 24 08:16 PM
Heery Christopher	CHIEF MEDICAL OFFICER	May 01 '24	Option Exercise	6.28	18,168	114,095	27,106	May 03 05:50 PM
Heery Christopher	CHIEF MEDICAL OFFICER	May 01 '24	Sale	51.33	18,168	932,557	8,938	May 03 05:50 PM
Ware Olivia C	Director	Apr 16 '24	Option Exercise	7.61	9,402	71,549	9,402	Apr 18 04:01 PM
Ware Olivia C	Director	Apr 16 '24	Sale	55.55	9,402	522,260	0	Apr 18 04:01 PM
Elghandour Rami	SEE REMARKS	Apr 01 '24	Sale	67.09	23,086	1,548,887	69,253	Apr 03 04:44 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Mar 22 '24	Option Exercise	6.28	20,000	125,600	50,303	Mar 26 08:52 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Mar 26 '24	Option Exercise	6.28	5,450	34,226	14,388	Mar 26 08:52 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Mar 22 '24	Sale	70.18	41,365	2,903,066	8,938	Mar 26 08:52 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Mar 26 '24	Sale	69.11	5,450	376,648	8,938	Mar 26 08:52 PM
Carroll Jill	Director	Mar 21 '24	Sale	70.55	504,263	35,575,755	1,479,148	Mar 25 05:30 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Mar 18 '24	Sale	69.34	6,825	473,255	9,485	Mar 18 08:49 PM
Ware Olivia C	Director	Mar 15 '24	Option Exercise	7.61	9,000	68,490	9,000	Mar 18 06:38 PM
Ware Olivia C	Director	Mar 15 '24	Sale	70.40	9,000	633,582	0	Mar 18 06:38 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Feb 09 '24	Sale	63.40	3,688	233,811	33,270	Feb 12 07:46 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Feb 08 '24	Sale	62.29	3,456	215,290	36,958	Feb 12 07:46 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Feb 12 '24	Sale	64.46	2,967	191,251	30,303	Feb 12 07:46 PM
Elghandour Rami	SEE REMARKS	Feb 09 '24	Sale	63.40	13,886	880,340	103,508	Feb 12 07:43 PM
Elghandour Rami	SEE REMARKS	Feb 08 '24	Sale	62.29	13,010	810,451	117,394	Feb 12 07:43 PM
Elghandour Rami	SEE REMARKS	Feb 12 '24	Sale	64.46	11,169	719,948	92,339	Feb 12 07:43 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Feb 07 '24	Option Exercise	0.00	22,555	0	40,414	Feb 09 04:08 PM
Elghandour Rami	SEE REMARKS	Feb 07 '24	Option Exercise	0.00	70,211	0	130,404	Feb 09 04:05 PM
Heery Christopher	Chief Medical Officer	Jan 04 '24	Sale	55.27	7,598	419,926	17,859	Jan 08 04:06 PM
Gilson Michelle	Chief Financial Officer	Jan 04 '24	Sale	55.27	8,514	470,551	16,310	Jan 08 04:04 PM
Elghandour Rami	See Remarks	Jan 04 '24	Sale	55.27	29,073	1,606,804	60,193	Jan 08 04:02 PM
Heery Christopher	Chief Medical Officer	Jan 03 '24	Option Exercise	0.00	16,519	0	25,457	Jan 04 07:32 PM
Elghandour Rami	See Remarks	Jan 03 '24	Option Exercise	0.00	53,097	0	89,266	Jan 04 07:29 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACLX

Arcellx Inc

Upgrade your FINVIZ experience